Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Advances in Upper GI Cancer Highlights: Webinar by VJOncology
Featuring presentations & expert discussions on the latest breakthroughs and clinical developments in upper GI cancers, with a focus on data and updates from recent international meetings, including ASCO 2025, ESMO GI 2025 & ASCO GI 2026.
Chair: Samuel Klempner | Moderators: Rutika Mehta, Sarah Derks
Perioperative, curative intent, and multimodality strategies in GC/GEJC
Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
Yelena Janjigian Memorial Sloan Kettering Cancer Center, NY, United States
Recurrence patterns in the prospective, randomized, controlled, multicenter phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy in patients with esophageal adenocarcinoma
Florian Lordick University of Leipzig, Leipzig, Germany
Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma
Zev Wainberg UCLA Health, CA, United States
CRITICS-II: A multicenter randomized phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Marcel Verheij Radboud University Medical Centre, Nijmegen, Netherlands
Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination: Results of the randomised PERISCOPE II trial
Judith Quik Netherlands Cancer Institute, Amsterdam, Netherlands
HER2-driven and biomarker-driven targeted therapies in GC/GEJC
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)
Joseph Tintelnot UKE Hamburg, Hamburg, Germany
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study
Kohei Shitara National Cancer Center Hospital East, Kashiwa, Japan
Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results
Elizabeth C. Smyth Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Zanidatamab (zani) + chemotherapy (chemo) ± tislelizumab (tisle) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): First results from the Phase 3 HERIZON-GEA-01 study
Elena Elimova The Princess Margaret Hospital, Toronto, Canada
Advances in pancreatic cancer
PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC)
Vincent Picozzi Virginia Mason Franciscan Health, Seattle, WA, United States
BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma
Benjamin Adam Weinberg Lombardi Comprehensive Cancer Center, WA, United States
Advances with I-O combination and novel immune checkpoint approaches in upper GI cancers
Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study
David Goldstein UNSW Sydney, Sydney, Australia
SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)
Ian Chau The Royal Marsden NHS Foundation Trust, London, United Kingdom
Domvanalimab (dom), zimberelimab (zim), and FOLFOX in first-line (1L) advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC): 26-month update from EDGE-Gastric, arm A1
Yelena Janjigian Memorial Sloan Kettering Cancer Center, NY, United States
Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)
Samuel Klempner Massachusetts General Hospital, Boston, MA, United States
Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Kohei Shitara National Cancer Center Hospital East, Kashiwa, Japan
